A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Exclusion criteria

• . Dexamethasone resistant myeloma based on last therapy. Patients are defined as being refractory to high-dose dexamethasone if they achieved less than a partial response, or developed progressive disease within 6 months of discontinuing dexamethasone, or dexamethasone was discontinued because of ≥Grade 3 dexamethasone-related toxicity. High-dose dexamethasone therapy is defined as \>500mg dexamethasone or equivalent over a 10-week period, whether administered alone or as part of the VAD regimen.
• . Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
• . Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
• . Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• . Use of any other experimental drug or therapy within 28 days of baseline.
• . Known hypersensitivity to thalidomide.
• . The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
• . Any prior use of lenalidomide.